Finally, the presence of anti-Ro-52 antibodies alone was associated with more than an eight-fold increased risk of ILD compared to those without anti-Ro-52 antibodies (adjusted OR = 8.42, 95% CI: 4.14–17.13; p < 0.001) (Table 2). Here, TRIM21 is linked to interstitial lung disease.